AMARIN CORP PLC\UK Excess Tax Benefit from Share-based Compensation, Operating Activities
AMARIN CORP PLC\UK (AMRN) reported Excess Tax Benefit from Share-based Compensation, Operating Activities of -$641.00 thousand for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-08-06.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities · last filed 2015-08-06
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, operating activities for the quarter ending 2015-06-30 was -$89.00K, a 4550.00% decline year-over-year.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, operating activities for the quarter ending 2015-03-31 was -$552.00K.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, operating activities for the quarter ending 2014-12-31 was -$2.30M.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, operating activities for the quarter ending 2014-09-30 was $0.00.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, operating activities for fiscal 2014 was -$2.30M.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, operating activities for fiscal 2013 was -$361.00K, a 103.19% decline from fiscal 2012.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, operating activities for fiscal 2012 was $11.33M, a 169.92% increase from fiscal 2011.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, operating activities for fiscal 2011 was $4.20M, a 673.30% increase from fiscal 2010.
| Period end | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month |
|---|---|---|---|---|
| 2015-06-30 | -$89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$641.00K 10-Q · filed 2015-08-06 | -$2.94M derived: sum of 3 quarters · filed 2015-08-06 | -$2.94M derived: sum of 4 quarters · filed 2015-08-06 |
| 2015-03-31 | -$552.00K 10-Q · filed 2015-05-08 | -$2.85M derived: sum of 2 quarters · filed 2015-05-08 | -$2.85M derived: sum of 3 quarters · filed 2015-05-08 | -$2.85M derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-12-31 | -$2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | -$2.30M derived: sum of 2 quarters · filed 2015-03-03 | -$2.30M derived: sum of 3 quarters · filed 2015-08-06 | -$2.30M 10-K · filed 2015-03-03 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $2.00K derived: sum of 2 quarters · filed 2015-08-06 | $1.00K 10-Q · filed 2014-11-06 | -$1.33M derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.00K 10-Q · filed 2015-08-06 | -$1.33M derived: sum of 3 quarters · filed 2015-08-06 | -$1.36M derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-03-31 | -$1.00K 10-Q · filed 2015-05-08 | -$1.33M derived: sum of 2 quarters · filed 2015-05-08 | -$1.36M derived: sum of 3 quarters · filed 2015-05-08 | -$1.04M derived: sum of 4 quarters · filed 2015-05-08 |
| 2013-12-31 | -$1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | -$1.36M derived: sum of 2 quarters · filed 2015-03-03 | -$1.04M derived: sum of 3 quarters · filed 2015-03-03 | -$361.00K 10-K · filed 2015-03-03 |
| 2013-09-30 | -$37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $288.00K derived: sum of 2 quarters · filed 2014-11-06 | $966.00K 10-Q · filed 2014-11-06 | $2.19M derived: sum of 4 quarters · filed 2015-03-03 |
| 2013-06-30 | $325.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $1.00M 10-Q · filed 2014-08-07 | $2.23M derived: sum of 3 quarters · filed 2015-03-03 | $4.38M derived: sum of 4 quarters · filed 2015-03-03 |
| 2013-03-31 | $678.00K 10-Q · filed 2014-05-09 | $1.91M derived: sum of 2 quarters · filed 2015-03-03 | $4.05M derived: sum of 3 quarters · filed 2015-03-03 | $10.13M derived: sum of 4 quarters · filed 2015-03-03 |
| 2012-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $3.37M derived: sum of 2 quarters · filed 2015-03-03 | $9.45M derived: sum of 3 quarters · filed 2015-03-03 | $11.33M 10-K · filed 2015-03-03 |
| 2012-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $8.22M derived: sum of 2 quarters · filed 2013-11-07 | $10.11M 10-Q · filed 2013-11-07 | $12.73M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $6.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $7.96M 10-Q · filed 2013-08-08 | $10.59M derived: sum of 3 quarters · filed 2014-02-27 | $11.10M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $1.88M 10-Q · filed 2013-05-09 | $4.51M derived: sum of 2 quarters · filed 2014-02-27 | $5.02M derived: sum of 3 quarters · filed 2014-02-27 | |
| 2011-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $3.14M derived: sum of 2 quarters · filed 2014-02-27 | $4.20M 10-K · filed 2014-02-27 | |
| 2011-09-30 | $510.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $1.57M 10-Q · filed 2012-11-08 | ||
| 2011-06-30 | $1.06M 10-Q · filed 2012-08-08 | |||
| 2010-12-31 | $543.00K 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |